A comprehensive view of Approved Drugs/Devices. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA approves GSKs oral Jesduvroq daprodustat to treat anemia caused by chronic kidney disease in adults who have received dialysis for at least four months; CKD affect about 700 million patients worldwide, with one in seven developing anemia
Published: February 03, 2023 by GSK Group (GlaxoSmithKline)
FDA approves AstraZeneca and Amgen’s Tezspire tezepelumab in a pre-filled, single-use pen for patients aged 12 and older with severe asthma; Tezspire is the only biologic approved for severe asthma with no phenotype for use at home or doctor’s office
Published: February 02, 2023 by AstraZeneca AB
FDA approves Merck’s Keytruda injectable as adjuvant treatment following surgical resection and platinum-based chemotherapy for patients with Stage IB, II, or IIIA non-small cell lung cancer; 2.2 million cases of lung cancer diagnosed in 2020
Published: January 30, 2023 by ENP Newswire
Merck Animal Health gets FDA approval of expanded indication for Bravecto fluralaner chews for dogs; the chews treat and control Asian longhorned ticks, an invasive species found in over one-third of US that can carry viral, bacterial, protozoal agents
Published: January 26, 2023 by Business Wire
FDA approves Abbott's Proclaim XR spinal cord stimulation system to treat painful diabetic peripheral neuropathy for people who need alternatives to traditional treatment approaches; about 50% of adults with diabetes will develop peripheral neuropathy
Published: January 26, 2023 by Abbott Laboratories

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count